Medically reviewed by Dr. Saswato Majumdar, MBBS, MD (PM&R) | Last updated: August 14, 2026 | Reading time: 9 minutes
Quick Answer
The stroke neuroplasticity window is the first 90 days after stroke, during which molecular events in the peri-infarct zone create conditions for brain rewiring that will not recur at the same intensity. High-dose, task-specific rehabilitation during this window produces measurable cortical remapping. Most stroke units deliver less than one hour of therapy per day. The biology and the service delivery are not aligned, and the clinical cost is avoidable.
Key Takeaways
- The stroke neuroplasticity window opens within hours of ischaemic injury and begins closing at around three months. It is largely quenched by six months.
- BDNF expression, growth-associated protein upregulation, dendritic sprouting, and synaptogenesis in the peri-infarct zone all peak during this window.
- High-dose task-specific training during this window produces cortical remapping visible on functional MRI. The effective dose is several hundred movement repetitions per day, not the dozens most conventional therapy delivers.
- The DOSE trial and subsequent work show that greater amounts of arm rehabilitation in the acute and subacute phases lead to measurably better upper limb outcomes.
- Typical acute stroke units deliver less than one hour of therapy per day across all disciplines. The gap between the science and the service is not a knowledge failure. It is a systems failure.
- Individual clinicians can act now: advocate for early mobilisation at 24 to 48 hours, prescribe structured home programmes, and refer to high-intensity outpatient rehabilitation at the first opportunity.
What Is the Stroke Neuroplasticity Window?
There is a window after stroke during which the brain is primed for rewiring at a level that will not be replicated again. Neuroscientists have characterised it. Trialists have exploited it. And yet walk into most stroke wards and you will find patients receiving 30-minute physiotherapy sessions twice a week, largely because that is what the service can deliver.
The stroke neuroplasticity window is the first 90 days after stroke onset. Within hours of ischaemic injury, the peri-infarct zone (the tissue surrounding the stroke) enters a state of heightened biological receptivity to rehabilitation input. This is not a metaphor. It is a measurable cascade of molecular events that drives synaptogenesis, axonal sprouting, and motor circuit reorganisation at rates not seen in the uninjured adult brain (Bernhardt et al., 2017).
By around three months, this biological window begins to close. By six months, it is largely quenched. Recovery after six months is still possible, and the stroke recovery timeline extends meaningfully beyond the window. However, the rate and ease of change fundamentally shift. What we do in the first 90 days matters more than anything that follows.
What Happens Biologically in the First 90 Days After Stroke?
The evidence for a temporally limited sensitive period of heightened plasticity following stroke is now robust. The biological events are well characterised.
The Molecular Cascade in the Peri-Infarct Zone
In the first days to weeks following ischaemic injury, a cascade of events unfolds around the peri-infarct zone:
- Growth-associated protein upregulation (including GAP-43) promotes axonal sprouting and new synaptic contact formation
- Dendritic sprouting accelerates, creating new structural opportunities for circuit formation
- Synaptogenesis increases at rates not seen in the uninjured adult brain
- BDNF expression peaks, facilitating long-term potentiation and the consolidation of new motor circuits
Critically, these molecular events require input to direct them productively. Without high-repetition, task-specific practice, the biological material for recovery is present but unused. The window opens regardless of what rehabilitation the patient receives. Whether the window is used well is entirely determined by the quality and quantity of the rehabilitation input.
When the Window Closes
Neuroplasticity begins to close at around three months post-stroke. By six months, the growth-promoting biological milieu has largely returned to baseline. Hebbian strengthening of new pathways still occurs after this point, but it requires more effort to drive and produces smaller gains per unit of practice. This is the biological basis for the stroke recovery plateau that families and clinicians commonly encounter.
What Does High-Dose Early Rehabilitation Look Like?
Task-specific training delivered with sufficient intensity during the stroke neuroplasticity window produces cortical remapping that can be visualised on functional MRI. Studies show increased activation in ipsilesional sensorimotor areas and expanded motor cortex representations for affected limb movements following high-dose early rehabilitation.
The dose word matters. The evidence points consistently toward a specific standard.
The Effective Dose: Several Hundred Repetitions per Day
The evidence from dose-response analyses supports high-repetition, high-intensity, task-specific practice in the range of several hundred movement repetitions per day (Lang et al., 2015). This is not several hundred per week. It is per day. Most conventional therapy delivers dozens of repetitions per session, not hundreds.
What This Looks Like in Practice
| Therapy Component | Evidence-Supported Standard | Typical Acute Unit Delivery |
|---|---|---|
| Upper limb repetitions per session | 300 to 500+ | 30 to 60 |
| Total therapy per day | 3 to 5 hours | Under 1 hour |
| Task specificity | Matched to patient’s functional goals | General exercises |
| Frequency | Daily | 2 to 3 sessions per week |
The discrepancy in that table is the implementation gap. It is not subtle. It is a structural failure of the rehabilitation system to reflect the neuroscience of dose-dependent recovery.
For patients who access a high-intensity physiotherapy programme during the acute and subacute phase, the gap closes significantly. The biology is ready. The question is always whether the rehabilitation delivery can meet it.
What Does the Trial Evidence Show About Dose?
The DOSE trial and subsequent work have shown that greater amounts of arm rehabilitation delivered in the acute and subacute phases lead to better upper limb outcomes (Hayward et al., 2017). The dose-response relationship for motor recovery is not linear indefinitely, but within the therapeutic range most patients currently receive, more is consistently better.
The pooled biomarker and imaging data from Hayward and colleagues confirm that patients receiving higher doses of arm rehabilitation during the neuroplasticity window show measurably better upper limb outcomes at three and six months. The effect holds across a range of stroke severities and lesion locations.
The Ward et al. 2019 paper from the Queen Square intensive rehabilitation programme demonstrates the complementary point: even in chronic stroke, intensity matters (Ward et al., 2019). If intensity drives gains when neuroplasticity is at its most constrained, the effect during the open window is likely substantially larger. This remains an active area of trial development.
The Implementation Gap in Numbers
The Bernhardt et al. Stroke Recovery and Rehabilitation Roundtable Taskforce defined the problem clearly in 2017: recovery science has outpaced the service models designed to deliver it (Bernhardt et al., 2017). A typical acute stroke unit provides less than one hour of therapy per day across all disciplines. This is not a funding curiosity. It is a clinical mismatch with direct consequences for patient outcomes.
Why Are We Still Wasting This Window?
The honest answer to this question is structural, not scientific. The knowledge has existed for over a decade. The trials have been done. The dose-response relationship is established. The reasons the window is still being wasted are:
Staffing Ratios and Service Architecture
Therapist-to-patient ratios in most stroke units cannot deliver the dose the evidence supports. One physiotherapist serving 8 to 12 patients cannot physically provide the volume of supervised task-specific practice needed per patient per day.
The Economic Model of Inpatient Rehabilitation
Inpatient rehabilitation is reimbursed by bed-day or episode, not by therapy dose delivered. A unit that provides 45 minutes of therapy per patient-day costs the same to the payer as one that provides 3 hours. The incentive structure does not reflect the neuroplasticity science.
Discharge Timing
Many patients are discharged from acute settings before the stroke neuroplasticity window is meaningfully engaged, and transition to community rehabilitation that delivers even lower therapy doses with further delays.
This is the reckoning the blog’s title refers to. The science and the system architecture have not yet aligned. The clinical cost falls entirely on the patient.
What Can Individual Clinicians Do Inside an Under-Delivering System?
The clinician who accepts this situation as fixed is not being realistic. They are making a choice. Within a constrained system, the following actions are within scope.
Advocate for Early Mobilisation at 24 to 48 Hours
Advocate loudly for early mobilisation within the first 24 to 48 hours for haemodynamically stable patients. An important nuance from the AVERT trial: very aggressive, high-intensity mobilisation within the first 24 hours can worsen outcomes. The goal is gentle, progressive early mobilisation starting at 24 to 48 hours, not immediate high-intensity exertion. Sitting up, assisted standing, and gentle transfers are appropriate. The aim is to signal recovery, not to rush high-dose motor training before the patient is medically stable.
Prescribe Structured Home Programmes
Prescribe structured upper limb home programmes for the hours outside supervised therapy. Give the patient and family a daily repetition target, specific tasks, and a simple tracking sheet. A patient who performs 200 additional repetitions at home per day is adding meaningful dose to their neuroplasticity window, even if the inpatient service cannot deliver it.
Refer to High-Intensity Outpatient Programmes
Refer to high-intensity outpatient or inpatient neurorehabilitation programmes at the first opportunity. The HCAH inpatient stroke rehabilitation programme is specifically structured to deliver the therapy intensity that the 90-day window demands.
Be Honest With Patients and Families About the Window
For the patient’s sake, be honest that three months from now the biology will have shifted. What we do in this window will matter more than anything that follows. This is not a conversation designed to create anxiety. It is the information patients and families need to prioritise rehabilitation attendance and home practice during the most important biological phase of recovery.
Frequently Asked Questions
What is the stroke neuroplasticity window?
The stroke neuroplasticity window is the first 90 days after stroke, during which the brain produces elevated levels of growth-promoting molecules in the peri-infarct zone. This creates conditions for cortical rewiring that will not be replicated at the same intensity later. High-dose, task-specific rehabilitation during this window drives measurably better outcomes than equivalent therapy delivered after the window closes.
How many repetitions does a stroke patient need per day?
The evidence supports several hundred task-specific movement repetitions per day for upper limb recovery during the subacute phase. This is a dose most standard therapy sessions do not approach. High-intensity outpatient or inpatient programmes with structured home practice can help patients reach this threshold.
Does recovery stop after 90 days?
No. The stroke neuroplasticity window closing at 90 days does not mean recovery stops. It means the biological conditions that make recovery easiest begin to shift. Neuroplasticity continues throughout life. Chronic stroke rehabilitation programmes, including those using robotic therapy and neuromodulation, demonstrate real gains years after stroke. The window is about what is easiest, not what is possible.
Why does the average stroke unit deliver less than one hour of therapy per day?
The gap between evidence-supported therapy dose and actual delivery is a systems problem, not a knowledge problem. Staffing ratios, reimbursement models tied to bed-days rather than therapy dose, and discharge timing all contribute. Clinicians working within these constraints can advocate for change and maximise what is possible with home programmes and early specialist referral.
What is the DOSE trial and what did it show?
The DOSE (Dose Optimisation for Stroke Evaluation) trial examined the relationship between arm rehabilitation dose in the subacute phase and upper limb recovery outcomes. Combined with subsequent pooled data analyses, it showed that higher doses of arm rehabilitation during the neuroplasticity window produce measurably better upper limb function at 3 and 6 months. The dose-response relationship is consistent across stroke severities and lesion types.
Is early mobilisation always safe after stroke?
Gentle early mobilisation at 24 to 48 hours is safe and beneficial for most haemodynamically stable stroke patients. The AVERT phase III trial showed that very aggressive early mobilisation within 24 hours with very high frequency can worsen outcomes. The current clinical guidance is: gentle, progressive, goal-directed early mobilisation starting at 24 to 48 hours, not rest, and not aggressive exertion in the very first hours.
How can families support the neuroplasticity window at home?
Families can support the window by prompting daily practice of the specific movements or tasks prescribed by the physiotherapist or occupational therapist, keeping a simple daily repetition log, attending therapy appointments consistently, and reducing compensatory assistance (letting the patient attempt tasks rather than completing them). The home environment is where most of the daily hours are spent. It is also where most of the dose gap can be addressed.
Does BDNF supplementation help stroke recovery?
BDNF (brain-derived neurotrophic factor) is one of the key molecular drivers of the neuroplasticity window. Its expression peaks naturally after stroke. There is no evidence-supported BDNF supplementation protocol for human stroke recovery at this time. The most evidence-supported way to leverage BDNF during the window is intensive physical and cognitive activity, which drives endogenous BDNF release and activates the downstream plasticity pathways it enables.
Conclusion
The 90-day brain is not a metaphor. It is a measurable biological reality with direct clinical implications. The stroke neuroplasticity window opens within hours of ischaemic injury and closes, largely, by six months. During that window, high-dose, task-specific rehabilitation produces cortical change at a level that nothing else in stroke recovery medicine can match.
The science is not the problem. The architecture of stroke services is. Until that reckoning arrives at a systems level, the individual clinician has choices: advocate for early mobilisation, prescribe structured home programmes, refer early to high-intensity rehabilitation, and be honest with patients about the biology of time.
Three months from now, the window will be different. What we do today will not be replaceable by anything we offer later.
Medical Disclaimer
This article is for educational and clinical reference purposes and does not replace personalised medical advice. Early mobilisation and rehabilitation intensity should be tailored to the individual patient’s haemodynamic stability, medical status, and stroke severity. Consult a qualified neurologist or rehabilitation physician for individual management.
References
- Ward NS, Brander F, Kelly K. Intensive upper limb neurorehabilitation in chronic stroke: outcomes from the Queen Square programme. Journal of Neurology, Neurosurgery and Psychiatry. 2019;90(5):498 to 506.
- Bernhardt J, Hayward KS, Kwakkel G, Ward NS, Wolf SL, Borschmann K, et al. Agreed definitions and a shared vision for new standards in stroke recovery research: the stroke recovery and rehabilitation roundtable taskforce. Neurorehabilitation and Neural Repair. 2017;31(9):793 to 799.
- Patel J, Shim I, Agrawal DK. Interventions for neural plasticity in stroke recovery. Archives of Internal Medicine Research. 2025;8:246 to 258. ⚠️ Doctor to verify journal indexing before publish.
- Lang CE, Lohse KR, Birkenmeier RL. Dose and timing in neurorehabilitation: prescribing motor therapy after stroke. Current Opinion in Neurology. 2015;28(6):549 to 555.
- Hayward KS, Schmidt J, Lannin NA, Hyde SA, Linder SM, Rosenfeldt AB, et al. Are we armed with the right data? Pooled individual data review of biomarkers in people undergoing upper limb rehabilitation after stroke. NeuroImage: Clinical. 2017;13:310 to 319.
